Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Brexit: Issues And Opportunities As UK Life Sciences Define A New Relationship In Europe

Executive Summary

It's fair to say that the outcome of the June 23, 2016 referendum on the UK’s membership of the EU stunned not only the nation, whether you voted to leave or remain, but sent shockwaves through Europe and beyond. The UK’s pharmaceutical industry made no secret of its stance: it was all about remain – but it got a Brexit instead. Scrip’s Sukaina Virji gathered a group of pharma industry experts who spent the summer working on making the best of the situation around a table and recorded their insightful discussion. Listen to the full conversation here.

Brexit: Issues And Opportunities As UK Life Sciences Define A New Relationship In Europe

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC097406

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel